Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 23,418 | 14,074 | 37,466 | 23,195 |
| General and administrative | 8,099 | 5,242 | 14,953 | 10,789 |
| Total operating expenses | 31,517 | 19,316 | 52,419 | 33,984 |
| Loss from operations | (31,517) | (19,316) | (52,419) | (33,984) |
| Other (expense) income: | ||||
| Change in fair value of derivative liability | (1,010) | (2,530) | (530) | (2,150) |
| Change in fair value of contingent consideration | (6,574) | — | (6,574) | — |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's R&D?
- Avalo Therapeutics (AVTX) reported R&D of $23.42M in Q2 2026.
- How has Avalo Therapeutics's R&D changed year-over-year?
- Avalo Therapeutics's R&D increased by 66.4% year-over-year, from $14.07M to $23.42M.
- What is the long-term trend for Avalo Therapeutics's R&D?
- Over 4 years (2021 to 2025), Avalo Therapeutics's R&D has grown at a -4.3% compound annual growth rate (CAGR), from $59.84M to $50.09M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Avalo Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude